Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) is 7.96% higher on its value in year-to-date trading and has touched a low of $18.51 and a high of $64.54 in the current 52-week trading range. The PHAT stock was last observed hovering at around $35.43 in the last trading session, with the day’s loss setting it -1.81%.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $33.62, the stock is -25.69% and -16.65% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 86520.0 and changing -5.11% at the moment leaves the stock 1.77% off its SMA200. PHAT registered a gain of 1.88% in past 6-months. The firm has a 50-day simple moving average (SMA 50) of $42.90 and a 200-day simple moving average (SMA200) of $35.01.
The stock witnessed a -20.48% loss in the last 1 month and extending the period to 3 months gives it a 30.01%, and is -26.14% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.03% over the week and 10.64% over the month.
Distance from 52-week low is 81.63% and -47.91% from its 52-week high.
Phathom Pharmaceuticals Inc. (PHAT) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Phathom Pharmaceuticals Inc. (PHAT) is a “Overweight”. 3 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Phathom Pharmaceuticals Inc. quarterly earnings per share for the current quarter are estimated at -$0.56.The EPS is expected to grow by 88.30% this year.
Phathom Pharmaceuticals Inc. (PHAT) Top Institutional Holders
66 institutions hold shares in Phathom Pharmaceuticals Inc. (PHAT), with 4.62M shares held by insiders accounting for 18.38% while institutional investors hold 92.47% of the company’s shares. The shares outstanding are 32.47M, and float is at 23.61M with Short Float at 4.31%. Institutions hold 75.47% of the Float.
The top institutional shareholder in the company is Frazier Management LLC with over 7.28 million shares valued at $188.08 million. The investor’s holdings represent 25.15% of the PHAT Shares outstanding. As of Mar 30, 2020, the second largest holder is RA Capital Management, L.P. with 3.71 million shares valued at $95.73 million to account for 12.80% of the shares outstanding. The other top investors are Invesco Ltd. which holds 2.08 million shares representing 7.17% and valued at over $53.59 million, while Medicxi Ventures Management (Jersey) Ltd holds 7.14% of the shares totaling 2.07 million with a market value of $53.39 million.
Phathom Pharmaceuticals Inc. (PHAT) Insider Activity
A total of 4 insider transactions have happened at Phathom Pharmaceuticals Inc. (PHAT) in the last six months, with sales accounting for 1 and purchases happening 3 times. The most recent transaction is an insider purchase by RA CAPITAL MANAGEMENT, L.P., the company’s 10% Owner. SEC filings show that RA CAPITAL MANAGEMENT, L.P. bought 117,600 shares of the company’s common stock on Apr 01 at a price of $24.86 per share for a total of $2.92 million. Following the purchase, the insider now owns 3.83 million shares.
Phathom Pharmaceuticals Inc. disclosed in a document filed with the SEC on Mar 31 that RA CAPITAL MANAGEMENT, L.P. (10% Owner) bought a total of 30,600 shares of the company’s common stock. The trade occurred on Mar 31 and was made at $24.55 per share for $0.75 million. Following the transaction, the insider now directly holds 3.71 million shares of the PHAT stock.
Still, SEC filings show that on Mar 27, RA CAPITAL MANAGEMENT, L.P. (10% Owner) acquired 30,000 shares at an average price of $24.60 for $0.74 million. The insider now directly holds 3,676,808 shares of Phathom Pharmaceuticals Inc. (PHAT).